Introduction
Progress in the field of cancer gene therapy has continued significantly as evidenced by the five products that are now in final phase III clinical development. Adenoviral (Ad) herpes simplex virus-thymidine kinase (HSV-tk) 'suicide gene therapy' is being evaluated in patients with glioblastoma (Ark Therapeutics). Another Ad-based product advexin (Ad p53) has been used for the treatment of head and neck cancers and for Li-Fraumeni syndrome tumors (Introgen Therapeutics). A related Ad p53 product is approved for the treatment of head and neck cancer in China (Sibiono). There are three immunogene therapies that are also in phase III clinical development. One of these treatments is a prostate cancer vaccine composed of allogeneic prostate cancer cell lines transduced to express the immunostimulatory cytokine GM-CSF (Cell Genesys), whereas another genetically engineered vaccine is targeted to non-small-cell lung cancers where tumor cells are genetically modified by antisense vectors to inhibit expression of the immune suppressor transforming growth factor-b (TGF-b) (NovaRx). Direct tumor injection of a nonviral vector expressing an allogeneic major histocompatibility complex antigen is being developed for the treatment of melanoma (Vical). More information regarding the status of these clinical programs may be found on the sponsors' websites.
The increased clinical experience afforded by these and other gene therapy clinical programs is defining the utility and limitations of currently available vector systems. We describe some of the most recent developments in the continuously evolving field of cancer gene therapy that are designed to provide further efficacy and safety improvements.
New targets for cancer gene therapy
Synovial sarcoma X breakpoint 2 (SSX2) is a cancertestes gene expressed in the testis and at very low levels in the thyroid gland of normal individuals, while being expressed in various tumor types including 50% of melanomas.
1 SSX2-interacting protein (SSX2IP) is a leukemia-associated antigen expressed in 33% of acute myeloid leukemia (AML) patient samples at presentation but not in normal donor hematopoietic samples. 2 In contrast to the literature on the intracellular localization of SSX2IP constructs, 1 the expression of de novo SSX2IP has been shown to occur predominantly on the surface of AML cells and this expression peaked during mitosis. 3 Overexpression of SSX2IP was demonstrated by microarray in patients with the t(15;17) translocation and was found to strongly correlate with the overexpression of genes whose proteins are involved in cell cycle. 4 Conversely, an underexpression of SSX2IP in patients with a t(8;21) translocation correlated with an underexpression of cdc20, an activator of the anaphase-promoting complex (APC), an E3 ubiquitin ligase in the ubiquitinmediated proteolysis pathway. 5 The APC ubiquitin ligase helps regulate the metaphase/anaphase transition and exit from mitosis/G 1 entry through the ubiquitination of various substrates. Decreases in CDC20 protein expression have been shown to be associated with the increased rate of aneuploidy seen in t(8;21) patients. 6 Guinn suggested that immunotherapy targeting AML patients using SSX2IP would be most effective when treating patients with the t(15;17) translocation and SSX2IP antibody (Ab) targeting could be used to reduce the tumor load in autologous 'rescue' transplants.
The transcription factor activator protein-2a (AP-2a) has been shown to inhibit growth, 7 and apoptosis induction by AP-2a has been shown to involve transcriptional repression of Bcl-2 and activation of mitochondrial apoptotic pathway. 8 The exogenous expression of AP-2a inhibits cyclin D2/CDK4 activity, resulting in G 1 arrest. This inhibition is brought out by AP-2 interfering with MYC binding to the cyclin D2 promoter and thus represses the activation of cyclin D2. Expression of AP-2a gene is lost due to hypermethylation in rhabdomyosarcoma and AP-2a inhibits the growth of cells by inducing cell cycle arrest and apoptosis. The use of AP-2a is now being explored as a therapeutic strategy either alone or in combination with chemotherapy.
FUS1, a tumor suppressor gene was identified by cytogenetic studies on lost regions on chromosomes. FUS1 is located on the 3p21.3 chromosome and has been shown to be lost in a large number of lung cancers. 9 Cancer gene therapy based preclinical studies showed FUS1 induced apoptosis in lung cancer cells and was more effective at doing this than p53. 10 Preclinical results where the systemic delivery of the FUS1 gene encapsulated in DOTAP-cholesterol lipid-based nanoparticles reduced lung metastasis and increased animal survival. [11] [12] [13] On the basis of these preclinical studies, FUS-nanoparticle-based systemic therapy in a phase I clinical trial for human nonsmall-cell lung cancer patients has been initiated by Rajagopal Ramesh (MD Anderson Cancer Centre, USA). This is the first systemic nanoparticle-based cancer cancer gene therapy clinical trial in the world and the trial has now achieved preliminary results on the first 13 patients who have received FUS1-nanoparticle treatment. The treatment was shown to be well tolerated with no significant toxicity and evidence of antitumor activity in some of the patients' has also been demonstrated. The challenges of progressing laboratory findings into the clinic have been noted by Ramesh and although the early clinical results are promising, the final outcome of this ongoing trial will not be known for a number of years.
Viral vectors
A large number of groups which had started their work with retroviral (RV) vectors, subsequently switched to Ad vectors when, based on phase III clinical trials, it became evident that RV vectors had poor transduction efficiency in human tumors.
14 Rita Mulherkar and her group began by using mouse RV vectors carrying HSV-tk in a xenograft nude mouse model for head and neck squamous cell carcinoma. 15, 16 The Mulherkar group have been working towards increasing infectivity and tumor cell killing using an Ad-HSV-tk system. They have shown that increased infectivity and transgene expression could be achieved with Ad vectors in the presence of the histone deacetylase inhibitor-valproic acid. The group also started work on nonviral vectors to target short hairpin RNAs (shRNA) in order to sensitize tumor cells to chemotherapy and radiotherapy. Mulherkar has also described the cancer gene therapy lab at newly formed Advance Centre for Treatment Research and Education in Cancer centerthe first of its kind in India, based in an academic institute, which had been constructed for the preparation of clinical grade reagents including vectors for cancer gene therapy. It is hoped that the first phase I cancer gene therapy clinical trial will soon be carried out in India.
Ad-associated vectors (AAVs) are also being used to induce apoptosis 17 through the incorporation of the very short half-life of soluble TNF-related apoptosis-inducing ligand (TRAIL) in monkeys. AAV2/5-s-TRAIL has been shown to inhibit the growth of human lung adenocarcinoma (A549) xenografts in nude mice 18 without toxicity to normal tissues. AAV-sTRAIL prolonged the survival of the mice when they have human lung adenocarcinoma, without the virus traveling to the liver. AAV-mediated sTRAIL cancer gene therapy suppresses liver metastases. 19 AAV-sTRAIL suppresses the growth of human hepatocellular carcinoma (HCC). 20 The preclinical data is being used as the basis for phase I clinical trials. The novel anti-DR5 (AD5-10) monoclonal Ab binds to DR5 at a different site from TRAIL, 21 and AD5-10 and sTRAIL synergize when inducing apoptosis. AD5-10 induces the caspase cascade. Caspase-8, -10, -3 and PARP cleavage is observed. If caspase inhibitor is added then this effect is prevented. The tumoricidal activity of AD5-10 against human HCC (SMMC-7721) and lung cancer can be seen in nude mice. AD5-10 scFv suppresses the growth of lung tumors in animal models. rAAV-mediated scFv expression could overcome the pitfalls of rapid blood clearance and the difficulties associated with the large-scale production of Abs. 22 Agonistic ligands of formyl peptide receptor like 1 (FPRL1), a member of G-protein-coupled receptor family, enhance endogenous TRAIL expression both in vitro and in vivo. This expression of TRAIL mediated by FPRL1 is regulated by NF-kB and suppresses implanted liver cancer growth in the mouse model, 23 providing a possible novel therapeutic option for the cancer gene therapy of cancer. Sara Collins (Cork Cancer Research Centre, Ireland) showed that reporter genes in AAV-2 can elicit higher levels and extended durations of transgene expression in murine tissues (tumor, liver, muscle) than plasmid-based genes, when delivered in conjunction with electroporation or ultrasound. When murine tumors were treated with GM-CSF and B7-1 on plasmids or AAV-2, more than 60% of tumor-bearing mice treated underwent a complete regression. 24 Complete responders were specifically resistant to tumor rechallenge. No toxicity was observed in athymic or immunocompetent mice treated with AAV-2 particles subcutaneously (s.c.) or intravenously (i.v.).
These data, among others, suggest the under-utilized potential of AAV in cancer gene therapy applications. Indeed, rAAV serotype 2 is now being used to treat angiogenesis. Cancer gene therapy of angiogenesis is of particular interest because angiogenesis is requisite for the development and spread of most cancers, including lung. Ruian Xu (Molecular Medicine Engineering Research Center, Hong Kong University) has found that rAAV2/5 is more effective than rAAV2/1, rAAV2/2 or rAAV2/8 at transducing Lewis Lung carcinoma cells. In vitro vasostatin has been shown to suppress endothelial cell proliferation, endothelial tube formation and induce morphological changes in endothelial cells, including those associated with apoptosis. rAAV2/5-vasostatin was shown to lead to tissue-specific gene expression for up to 6 months following intratumoral injection without any obvious side effects in immunocompetent mice. In s.c. A549
xenografts, rAAV2/5-vasostatin treatment inhibited tumor growth with an accompanied reduction in microvessel density, vessel maturation and increased apoptosis in tumor tissues. In primary orthotopic xenografts, the reduction of microvessel density contributed to significant inhibition in lymph node metastases but not the primary tumor growth. rAAV2/5-vasostatin treatment not only reduced spontaneous pulmonary metastases, but also inhibited primary tumor growth in a spontaneous pulmonary metastases model. Taken all together, these studies demonstrate the efficacy of rAAV2/5-vasostatin in anti-angiogenic cancer gene therapy and provide the basis of a rAAV2/5-vasostatin clinical trial for the treatment of lung cancer.
Oncolytic viruses
The use of Ad to target the TGF-b receptor 25 was described by Prem Seth (Northwestern University, Chicago, USA) in 1999 at the first International Society for Cell and Gene Therapy of Cancer (ISCGT) meeting held in London, UK. The approaches used have not changed much since and whichever approach is used the main problem remains how to get the therapeutic gene in to the tumor. With the Ad vector, all 35 kb can be replaced without modifying the viral capsid. Seth 26 and Roth 27 independently made Ad-vectors expressing p53 tumor suppressor gene in the mid-1990s. A similar virus is now being used in clinical trials in China. 28 Replication-deficient Ad have been made expressing various tumor suppressor genes (such as p16, p27, VHL and p53), genes targeting angiogenesis and for immunotherapy. p53 till date has been the most efficacious. [29] [30] [31] [32] Ad wild-type (WT) p53 induces antitumor activity through the following mechanisms: However, the main limitation is the fact that E1 is replication defective and so there is no spread of the therapeutic virus through the tumor mass. Now there is a move to use oncolytic viruses as a potent anticancer drug. TGF-b1 is a poor prognostic marker of metastases in breast cancer. TGF-b binds TGFbRII and initiates Smaand Mad-related protein (SMAD)-dependent signaling. Armed oncolytic Ad.sTbRFc targeting TGF-b signaling has two components. The viral component is an E1A mutant that prevents E1A proteins from binding with Rb and p300 and is replication competent in tumor cells. Any cancer can be targeted with this virus. The second component is soluble TGFbRII fused with Fc protein (TGFbRIIFc). The half-life of TGFbRII in the blood is 4 h but Seth's group have made a fusion protein which has a half-life of 14 days. 25 The idea behind this therapy is that soluble TGFbRIIFc has to go to the blood. Infection of cancer cells with Ad.sTbRIIFc produces sTGFbRIIFc and causes viral replication. Direct intratumoral inoculation of Ad.sTbRIIFc causes inhibition of MDA-MB-231 xenografts in nude mice. Vectors could be delivered systemically and be controlled by tumor-specific promoters such as a modified hTERT promoter to drive Ad replication. Systemic administration of mhTAd.sTbRIIFc results in inhibition of tumor growth although administration via the i.v. route causes the virus to go to the liver also. However, it should be noted that although the virus is replication deficient in the liver, it can still make the protein which leads to tumor regression or failure of the tumor to form. sTGFbRIIFc can bind TGF-b and inhibit SMAD phosphorylation and tumor cell invasion.
Localized tumor destruction can be achieved by replication-competent Ad (oncolytic Ad) through the proliferation of the virus in tumor cells, which can lead to stimulation of a host systemic immune system. E1A transactivates both viral and cellular genes, which are critical for the productive viruses. The midkine (MK) gene is expressed in fetal brain but not in adult brain. It was also found to be expressed in HCC and esophageal cancers. 33 A total of 14 out of 15 HCC cancers were positive for the MK gene but not in the equivalent noncancerous tissues. Ad5F35 is 100 times more cytotoxic than conventional Ad5 and is a very useful for the treatment of human tumors.
Development of novel cancer gene therapy treatments
siRNA Small-interfering RNAs (siRNAs) have been developed that target two sites on human immunodeficiency virus (HIV). 34 This cancer gene therapy offers patients with HIV a much needed alternative to current best treatment highly active antiretroviral therapy (HAART). Although HAART has dramatically reduced the progression of HIV, there are problems with patient compliance, expense and side effects. Most patients with HIV do not want to be subjected to a life-long treatment for their disease. Jiing-Kuan Yee (City of Hope Medical Centre, Duarte, USA) is also developing shRNAs under the control of the potent H1 promoter. Yee described the qualities of a successful vector -efficient transduction, optimal expression of the transgene and safety. His group have developed the first lentiviral vector (LV) from an academic campus to be approved by the FDA for clinical trial. He described the strategy of using multiple siRNA to target HIV as a potential treatment of HIV infection in AIDS-affected lymphoma patients. In order to increase transgene expression, Yee's group designed LVs flanked by the chicken hypersensitive site-4 chromatin insulator element along with LCR from the human b-globin locus and observed increased expression of b-globin. They also demonstrated successful correction of b-thalassemia phenotypes with the b-globin vector-transduced hematopoietic stem cells in a nude mouse model, although it remains to be determined whether the insulator sequence can prevent aberrant activation of gene expression surrounding the vector integration site.
Pseudotyped LV Suicide cancer gene therapy using pseudotyped LV is a very attractive therapeutic strategy for human glioblastomas. The therapeutic efficacy of LV vectors pseudotyped with the glycoprotein of lymphocytic choriomeningitis (LCMV GP) and vesicular stomatitis virus glycoprotein (VSV-G) carrying HSV-tk suicide gene has been shown for intracranial rat glioma. Both of the pseudotyped LV vectors give promising results in the rat 9 l glioma model. 35 LCMV GP could successfully eradicate mouse tumors with 100% long-term survivors and it has been shown that normal brain cells transduced with VSV-G pseudotypes contributed significantly to bystander mediated killing of tumor cells.
Cloaking viruses
Many tumors are susceptible to killing by viruses because of acquired deficiencies in their innate immune defenses. The problem with most viruses used for cancer gene therapy is their inability to spread through the tumor mass. ONYX-017 differs from ONYX-015 by virtue of its WT E3 region but it failed to show impressive in vivo activity. Even the injection of large volumes of virus does not improve the spread of virus through the tumor mass and the problem with injecting larger volumes of virus is that it leaches through to the liver. This is mostly due to the tumor being a high-pressure environment. When injecting virus into tumors, Len Seymour (Oxford University, UK) and his group use a surgical glue to stop the fluid seeping back out through the site of administration. The Seymour group are using a combination of virotherapy and anti-angiogenic therapy to improve tumor killing. Seventy percent of patients with malignant cancer will die of metastases. Delivery of viral particles (v.p.s) by the blood stream is not very effective as this is an aggressive environment consisting of Abs, complement and T cells and once past these the v.p.s have to make it through the endothelial membrane and subendothelial connective tissue on their journey to the tumor cells. The Seymour group have previously shown that Ad binds to human blood cells and PCR analysis was used to investigate Ad levels in the blood versus the plasma of Ad-injected patients. 36 They showed that in humans, 90% of Ad was present on the blood cells whereas in mice (in a model mimicking the human situation), the Ad was mostly in the plasma. When they transfused NOD/SCID mice with human blood cells they found again that the majority of the Ad was bound to the blood cells. In humans, it is the red cells, which can bind Ad and prevent Ad getting to the tumor. Even with increasing Ad concentrations, the percentage of Ad in the plasma ranged from 0.2 to 0.5%. However, the results depended on the anticoagulant used. When blood was in the presence of anticoagulant citrate dextrose, citrate phosphate dextrose, heparin, hirudin or no anticoagulant to obtain serum, the virus bound to the blood cells, however when the blood was heat treated or in the presence of EDTA then the Ad was found in the serum. The other major focus of the group is the cloaking of Ad virus with multivalent, reactive polymers. 37 These polymers prevent hepatic infection. Seymour's group have shown that the use of a predose of Ad can 'fool' Kupffer cells so that the second dose is predominantly free to infect. They also showed that Kupffer cells can be 'knocked out' with bisphosphonate liposomes. A regular virus in the presence of clodronate liposomes has a half-life of 3 min in the blood, whereas a coated virus in the presence of the same has a half-life of 2 h; however, the virus still has difficulties getting through the interstitial connective tissue. Polymercoated Ad5 mediates greater tumor transduction and decreased liver transduction than unmodified Ad5. Charlotte Dalba (Epixis SA, Paris, France) summarized one of the main themes of the ISCGT India meeting with her quote 'mice lie, and monkeys don't tell the truth'. She suggested that we should not waste time developing mouse models when there is increasing evidence that mouse models of cancer are not the most productive or effective use of research money and time. There is increasing evidence for going straight to treatment rather than optimizing cancer treatment for a different organism with an artificial cancer (injection of vast numbers of cancer cells into naı¨ve animals, nonprimary cells which have been grown extensively in culture, etc.). This is nicely exemplified by Seymour's data (described in section 'Cloaking viruses') in which he demonstrates a clear difference between mice and humans with regards to where Ad sticks when administered into the peripheral blood.
Clinical trials
The collective experience of gene therapy clinical trials has identified useful vectors for clinical application along with the recognition of potential toxicities related to particular vectors in specific disease states. Ad vectors which may cause inflammation and fevers should be avoided in patients with orthnithine transcarbamylase deficiency or related metabolic conditions where catabolic insults such as fever may prove fatal. 40 It is now known that a few of the severe combined immunodeficiency (SCID) children who have been given cancer gene therapy with RV vectors have subsequently developed lymphoma. 41, 42 However, an understanding of the mechanisms involved in these adverse events permit improved and appropriate clinical application of these or other vector analogous to other drugs that have toxicity in some clinical settings but are appropriately and beneficially used in others (reviewed in Teo et al.
43
). Most patients present with SCID/CID in the first year of life and more than 90% are cured by an allogeneic bone marrow transplantation. The problem lies when there is no suitable BM donor. In these cases, patients receive a half-matched transplant from one parent. Survival in these cases is relatively poor with potential for severe side effects due to the chemotherapy, and toxicity associated with receiving mismatched cells. Therefore, these SCID patients are a good target for cancer gene therapy. SCIDX1(1) aberration is caused by mutations of the common cytokine receptor gamma chain, which is a component of the interleukin (IL)-21R, IL15R, IL-9R, IL-7R, IL-4R or IL-2R complexes. Of particular appeal in this therapy is that SCID-X1 corrected cells have a major selective growth and survival advantage, with a notable outgrowth in the genetically modified cells. In phase I/II clinical trials, the corrected gene integrates into the genome to give a stable gene transfer which is essential for hemopoietic disorders, so the stem cell transfers to the progeny (reviewed in Thrasher 44 ). Of the 10 patients treated so far by Adrian Thrasher (Institute of Child Health, London, UK) and his group, the lymphocyte recovery and return of CD3 levels to functional levels occurred within 6 months of treatment. All patients achieved a good immunological reconstitution. In the lab there was a normal response of T cells to mitogen or T-cell receptor (TCR) stimulation. Molecular spectrotyping showed that the TCR diversification was similar to that seen in age-matched healthy children. When vaccinated, the SCID children who had received cancer gene therapy sero-converted to produce IgG and IgM in response to antigens. However, the reconstituted humoral immunity was probably not as robust as the T-cell immunity, which was achieved. This treatment does not work with all patients. In older patients, thymopoiesis cannot just be started up again probably due to thymic involution. 45 As mentioned earlier, four of the patients in the Parisian clinical trial developed lymphoma and more recently a fifth case has occurred in a London patient. With SCID cancer gene therapy, the RV-modified cells each receive one copy of the transgene, but there are multiple integration events in different cells. A particular benefit of this treatment is that children do not need to receive chemotherapy to allow the modified cells to engraft. However, it should be noted that vectors favor going into regions of the genome that are near transcriptional start sites and favor integration into genes which are highly expressed. 46 In the Paris clinical trial, three of the four patients had integration of the virus into the LMO-2 gene and a gross increase in expression of LMO-2. Overall, cancer gene therapy is a highly effective therapy for SCID-X1 and ADA-deficient SCID and is promising for other hemopeitic disorders. Thrasher noted that much has been learnt from these studies particularly regarding the risk of the vector and its insertional preferences affecting other genes but that the development of newer vectors is likely to significantly diminish risks.
Tumor cells can be immunogenic as demonstrated by the list of antigens, which can be recognized by T cells in cancer patients; however, tumor editing and immune editing shape the response of the immune system to cancer cells and vice versa. 47 56 and others, the group modified 32Dp210 cells to express CD80, IL-2 or both and showed that the combination of B7-1 and IL-2 led to tumor rejection in mice. 57 Mice injected with live tumor cells could subsequently reject the preestablished leukemia by a therapeutic vaccination using the same tumor cells that were modified to express B7-1 and IL-2. Thrasher helped with the putting together of the self-inactivating LV, so that IL-2 and CD80 were in a single expression cassette, such that IL-2 was secreted and CD80 was surface expressed. 58 One round of infection led to good expression rates in primary AML cells. 58 IFNg ELISpot after 1 week of stimulation showed that autologous AML cells could stimulate the proliferation of T cells. CBA bead arrays demonstrated the secretion of cytokines and CTL activation of donor T cells as well as the fact that AML/CD80 þ IL-2 cells could induce CTL activity in autologous T cells in vitro. This work showed that remission T cells were not anergized to AML cells and that AML cells are not resistant to CTL lysis. In addition, T cells stimulated with AML blasts transduced to express CD80 and IL-2 were better able to respond to unmodified autologous AML cells, suggesting specificity of the response. Farzin Farzaneh (King's College London, UK) talked about the two major obstacles to an antitumor response. Tumor editing of the immune system and immune editing of the tumor (reviewed in Chan et al.
47
). These are important issues for immune therapy. Tumor editing leads to chronic immune stimulation by cancer, or indeed a chronic infection, and induces loss of functional competence, anergy, clonal exhaustion, depletion and induction of regulatory T cells (Tregs). Klenerman et al. 59 described the three phases of T-cell stimulation. They are: (1) 'functional' when the T cells are Tetramer þ and functional assays are possible, (2) 'dysfunctional' or 'stunned' when the T cells are Tetramer þ and functional assays provide weak or negative results and (3) 'exhausted' where T cells are tetramer À and functional assays are negative. This has implications for therapeutic vaccine strategies and suggests that the most potent antigens may not provide the best results. Disease burden at the time of transplant has been shown to effect leukemia-free survival rates and so the clinical trial which should start shortly (overviewed in Chan et al. 47 ), using B7-1/IL-2 expressing AML whole cell vaccine, will incorporate the vaccine along with standard treatments and will be administered in first remission. When asked by Nori Kasahara (University of California Los Angeles, USA) why the group had chosen IL-2 rather than GM-CSF, which is often viewed as a more potent antitumor cytokine, Farzaneh explained that these studies started nearly 15 years ago and at that time IL-2 was a very good option. Nori Kasahara noted that not all studies have borne out the belief that GM-CSF is the most potent anti-cancer vaccine. Farzaneh mentioned his concern with IL-2 expanding Tregs and that the assessment of Treg activity will be one of the important immunological studies in the AML/CD80 þ IL-2 clinical trial. Miller's group and are now being used in several key in vivo proof of concept experiments involving animal models of disease. Promising data have now been generated by this group using an siRNA-ABC nanoparticle system, known as siFECTplus for the delivery of antihepatitis B virus siRNAs to the liver of a transgenic mouse model of this disease; the ameliorative effects of siRNA delivery appeared to be promising and on a par with anti-viral drug delivery. In addition, a new onco siFECTplus system for the delivery of siRNA to xenograft tumors in vivo has been developed. Magnetic resonance imaging studies are being used to assist in the design of this new onco siFECTplus system. Finally, a novel pDNA-ABC nanoparticle system known as pTRANSplus has been discovered that appears to transfect murine lung in vivo to a level on par with Ad-mediated effects. This result was matched with a report on the development of a pDNA construct that appears to be capable of long-term (46 months) epichromosomal expression in murine liver, post-hydrodynamic delivery. The secret appears to be the combination of so-called S/MAR regions with liverspecific promoter elements that synergize to maintain epichromosomal pDNA expression beyond the more usual 1-2 weeks after delivery.
Nonviral vectors

Immunotherapy
Breaking tolerance
There are a number of limiting factors with regards to the response of patients to vaccines, all of which are exacerbated by age. Albert Deisseroth (Sidney Kimmel Cancer Center, San Diego, USA) and his group have developed an Ad-sig-TAA/ecdCD40L vaccine for the treatment of older mice. [64] [65] [66] Mice start being treated when they are 18 months old, the equivalent of being a 50-year-old human. The group did try treating even older mice of 22 months of age but these tended to die of age-related illness during the course of the experiment before the effects of new treatments could be assessed. Administration of a vaccination regimen in which a single s.c. injection of the Ad-sig-TAA/ecdCD40L vector was followed by two s.c. injections of a booster TAA/ ecdCD40L protein to the old mice was shown to cause an increase in the percentage of CD8 þ Tetramer þ cells as compared with vector injections without the protein boost. The next question was whether injections with Ad-sig-rH2N/CD40L could induce an rH2N-specific immune response in rH2N anergic, H2N transgenic mice. The experiments showed that the administration of the vaccine starting during the first 6 weeks of life could suppress the development of mammary cancer at 8 months of life in 50% of the vaccinated mice. MUC-1 is another self-antigen that is overexpressed in 30% of breast cancers as well as in other epithelial neoplasms but is barely detectable in normal epithelial cells. Deisseroth's group showed that an Ad-sig-hMUC-1/ecdCD40L vector prime-hMUC-1/ecdCD40L protein boost vaccine could suppress the growth of hMUC-1 positive mouse tumors (Lewis Lung) even in old mice. The vaccination induces hMUC-1-specific CD8 þ cells and hMUC-1-specific Abs in hMUC-1 transgenic mice. The Abs induced in these mice were shown to bind to human biopsy specimens containing human breast and prostatic cancer. A phase I clinical trial has been approved by the FDA for breast cancer patient entry at University of California Los Angeles. The key inclusion criteria are women who have relapsed from surgery, have a partial response to salvage therapy and are stable on some form of biological therapy. A phase I clinical trial at the University of Chicago for prostate cancer has inclusion criteria of prostate cancer with rising prostate-specific antigen levels. This prostate cancer trial uses Ad-sig-hMUC-1/ ecdCD40L vector prime-hMUC-1/ecdCD40L protein boost to expand antigen-specific T cells in patients who have relapsed after irradiation to the prostatic bed. The Deisseroth group has also shown that the provision of the vaccine to donor leukocyte infusions (DLI) donors suppresses tumor growth more than the addition of DLI from unvaccinated donors following for administration of DLI to mice given total body irradiation and T-cell depleted BMT, whereas DLI alone does not. Once they show this method works, it may be worth combining the treatment with a strategy that removes Tregs (discussed in section 'Tregs (regulatory T cells)'). Farzaneh noted that the work by Deisseroth's group 'provides evidence that you can break self-tolerance, which is the Achilles heel of cancer gene therapy'.
Tregs (regulatory T cells)
The existence of Tregs, initially called 'suppressor T cells', is an old concept and was described in functional assays by Gershon et al. 67, 68 The problem was that there were no specific marker for Tregs and no way to characterize their function until 20 years later. Although this statement ignores two papers by Hall et al. in 1985, 69,70 describing a CD4 þ population, of CD4 þ CD25 þ T lymphocytes which were shown to be involved in transplantation tolerance. However, these studies appear to have been largely ignored by the scientific community. The whole field was changed when Sakaguchi et al. 71 reported that mice reconstituted with T cells depleted of CD4 þ CD25 þ cells developed autoimmunity. This landmark observation clearly established the concept of Tregs as key controllers of self-specific immune responses and likewise of autoimmunity. Tregs are now characterized as being FoxP3 þ (FoxP3 being a transcription factor). 72 However, FoxP3 is not expressed on the surface of Tregs and therefore cannot be used to purify them. Tregs have been implicated in many immune responses including protecting the fetus from rejection, preventing autoimmune disease and inflammation such as athrosclerosis (recently reviewed in Raimondi et al.
73
). Aif-Oufella et al. 74 showed that a Treg deficit exacerbates atherosclerosis in LDLR mice but if you reconstitute these mice with Tregs you can control the disease. Another example was experimental uveitis in mice. Terrada et al. 75 showed that Treg depletion exacerbates uveitis whereas Treg injection controls it. Tregs are also particularly important in chronic infections such as leishmanosis and malaria and are also involved in inhibiting immune responses against cancer.
Curiel et al. 76 has provided a convincing study in humans showing that Tregs are involved in human ovarian cancer. They showed that independent of the stage of the cancer, the levels of Tregs could be used to predict survival. In experimental tumor models, when Altogether, Tregs have a tremendous therapeutic potential. Injection or activation of Tregs could prevent autoimmune diseases, graft versus host disease and graft rejection, allergy, transgene and vector rejection. Problems arise with the production of clinical grade Tregs. This is why in vivo Treg generation would be an interesting approach. This can be achieved by an intrathymic injection of LV expressing a transgene. 77 Depletion of Treg could and probably should be an important part of any immunotherapy treatment of cancer. This is currently being tested in the context of leukemia relapse after allogeneic stem cell transplant. When the standard treatment by DLI is inefficient, a Treg depleted DLI to augment the antitumor effect is being tested. Preliminary results of such treatment are encouraging (Maury et al., in preparation).
Dendritic cell vaccines
There are two stages in the activation of dendritic cells (DCs): (1) antigen capture by immature DCs and (2) antigen presentation by mature DCs. Tumors express low levels of Fas ligand, which suppresses antitumor immune responses. IL-23, IL-12 and IL-27 are sequentially secreted from DCs. 78 IL-23p40 suppresses allo-graft rejection, whereas IL-27p28 is secreted as a monomer and inhibits immune responses. Masatoshi Tagawa (Chiba Cancer Center, Japan) said that secretion of IL-12 family cytokines from tumor cells produced antitumor effects and that soluble subunits of the IL-12 family inhibited cytokine-mediated responses. Oncolytic Ad expressing these cytokines could produce improved therapeutic effects. RV virus-like particle (VLP)-based vaccines RV VLP-based vaccines, 79 the particulate form of which is important for immunogenicity, [80] [81] [82] tend to be more efficient immunogens than nonparticulate recombinant virus subunits. They provide excellent boosters of classical vaccines based on recombinant viral vectors and vectored VLPs are currently being investigated. VLPs consist of one or more viral proteins, which assemble into particles and mimic the overall structure of WT v.p.s. Such particles have been produced from more than 30 different viruses and can be used both as homologous antigens and as platforms for heterologous antigens. Likewise, RV VLPs, based on the RV Gag protein can be homologous, expressing or not the RV envelope protein on their surface, or heterologous, pseudotyped with envelope proteins from different viruses. Increasing complexity can be achieved through insertion of epitopes of choice in the Gag or Env proteins. Immunizations with RV VLPs displaying a dominant T-cell epitope within the surface Env protein showed that the immune system can readily recognize such particles, which induced stronger immune responses than did the same T-cell epitope in Freund's adjuvant. 79 Epixis SA, in a statement made by Dalba (CEO, Paris, France), hopes to provide a treatment for hepatitis C virus (HCV), which would target approximately 3% of the world's population which is infected by HCV, and as such are subject to developing hepatic fibrosis, cirrhosis and carcinoma. The B-and T-cell responses are both important for HCV clearance. However, inducing neutralizing Abs is a challenge, as the interplay between HCV glycoprotein E2, serum highdensity lipoprotein (HDL) and the scavenger receptor B1 mediates protection from neutralizing Abs. 83 Epixis SA's vaccine strategy utilizes engineered HCV VLPs that provide induction of Ab responses that are broadly cross-neutralizing and not HDL sensitive.
Summary
Cancer gene therapy may be further improved by more efficient transfer of the genetic information, once in a human, to the target site. Even where physical targeting can locate the gene to the tumor, we are still hindered by the inability of the vector to move through and infect a large number of cells in the tumor mass (see comments on Seymour's work).
The move to using oncolytic replication effective vectors (see Seth and Tagawa's data) has the potential to overcome the problems previously associated with the inability of replication incompetent vectors to undertake intratumoral spread. This leaves concerns as to how to make the infection of tumor cells effective, although not leading to the infection of non-target cells. Modification of oncolytic viruses can lead to the infection in a tumor cell specific way. Two quite different achievements need to occur, how to get infective particles to the tumor site (we have reviewed some of the ways in which Seymour's group are developing new targeting systems), how to prevent the immune system clearing the infected cells, how to specifically target the tumor cells and how to allow tumor-specific spread.
To date serious adverse effects from gene therapy have been rare, consisting of the fatality of a patient with ornithine transcarbamylase deficiency, 40 the leukemia caused by cancer gene therapy in four SCID patients 41, 42 and the death of a patient who had received AAV-related tgAAC94, an investigational therapy for the treatment of inflammatory arthritis-although it was later proven that the death was unrelated to AAV. The results of the ongoing phase III clinical trials should be known within the next 12-18 months and it should be realized that for some patients in earlier phases I and II clinical studies clinical benefits have been realized. For patients receiving cancer gene therapy in the SCID trial (see Thrasher's work) their quality of life has progressed from regular hospital treatments and a debilitating lifestyle to a normal childhood. Even in light of problems with a similar trial in Paris and one patient in the London trial, parents of SCID children continue to seek cancer gene therapy treatment in the hope that it will give their offspring a normal family life, in spite of the wellpublicized risks.
More notice is also being taken of the tumor microenvironment and the effect this has both on the tumor's behavior and the ability to infect tumors in the presence of tumor stroma. These and other advances will be further updated at the next ISCGT meeting in China, http:// www.iscgt.org.uk/, to be held from 19 to 22 September 2008.
Abbreviations AAV, adeno-associated virus; Ab, antibody; Ad, adenovirus; AML, acute myeloid leukemia; AP-2a, activator protein-2a; APC, anaphase-promoting complex; CTL, cytotoxic T lymphocyte; DC, dendritic cell; DLI, donor leukocyte infusion; FPRL1, formyl peptide receptor like 1; HAART, highly active antiretroviral therapy; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; HDL, high-density lipoprotein; HIV, human immunodeficiency virus; HSV-tk, Herpes simplex virus-thymidine kinase; ISCGT, International Society for Cell and Gene Therapy of Cancer; LCMV GP, glycoprotein of lymphocytic choriomeningitis; LV, lentiviral vector; MK, midkine; pDNA, plasmid DNA; RV, retroviral; s.c:, sub-cutaneous; SCID, severe-combined immunodeficiency; shRNA, short hairpin RNA; siRNA, short-interfering RNA; SMAD, Sma-and Mad-related protein; SSX2IP, synovial sarcoma X breakpoint 2 interacting protein; TCR, T-cell receptor; TGF-b1, transforming growth factor-b 1; TRAIL, TNFrelated apoptosis-inducing ligand; Tregs, regulatory/suppressor T cells; TAA, tumor-associated antigen; VLP, virus-like particle; VSV-G, vesicular stomatitis virus glycoprotein; WT, wild type.
